Literature DB >> 30368636

Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.

P Vande Perre1,2,3, A Siegfried4,5, C Corsini6, D Bonnet2,7, C Toulas2,5, N Hamzaoui8, J Selves3,4,5, E Chipoulet2,7, J S Hoffmann3,5, E Uro-Coste3,4,5, R Guimbaud9,10,11,12.   

Abstract

Germline mutations of the POLE gene are responsible for polymerase proofreading-associated polyposis syndrome (PPAP). These mutations were hypothesised to predispose to extra-gastrointestinal tumours (ovary, endometrium, brain), but this association has not been confirmed so far. We report a family with an autosomal dominant inheritance of PPAP due to a c.1089C>A; p.Asn363Lys mutation in the proofreading exonuclease domain of POLE. Ten patients presenting a history of colorectal tumours and three patients with polyposis are indexed in this family. Three carriers (including siblings and a distant cousin at 30, 45 and 52 respectively) and another member (at 37 not tested) presented glioblastoma. This is the second family reported to carry this mutation. Among the four glioblastomas in the family that we report, both show similar pathology: giant cell glioblastoma. These cases suggest that the c.1089C>A germline POLE mutation may confer an increased risk of brain cancer [incidence 17.4% (4/23) in mutation carriers combining the two families]. More observations are needed to support this hypothesis. It seems that not all mutations of POLE are equally associated with extra-gastrointestinal tumours. Although carriers of a mutation responsible for PPAP should benefit from screening for colorectal and uterine cancer, due to the rapid evolution of glioblastoma the value of neurological follow-up and brain imaging screening remains questionable. Nevertheless, considering the limitations of standard therapy for glioblastoma, mutation status could be useful for targeting therapy. The biological mechanism linking POLE mutation to glioblastoma remains to be determined.

Entities:  

Keywords:  Giant cells; Glioblastoma; POLE; PPAP; Polymerase epsilon; Proofreading

Mesh:

Substances:

Year:  2019        PMID: 30368636     DOI: 10.1007/s10689-018-0102-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  11 in total

1.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

Authors:  Quinn T Ostrom; Haley Gittleman; Paul Farah; Annie Ondracek; Yanwen Chen; Yingli Wolinsky; Nancy E Stroup; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2013-11       Impact factor: 12.300

2.  Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.

Authors:  E Zeynep Erson-Omay; Ahmet Okay Çağlayan; Nikolaus Schultz; Nils Weinhold; S Bülent Omay; Koray Özduman; Yavuz Köksal; Jie Li; Akdes Serin Harmancı; Victoria Clark; Geneive Carrión-Grant; Jacob Baranoski; Caner Çağlar; Tanyeri Barak; Süleyman Coşkun; Burçin Baran; Doğan Köse; Jia Sun; Mehmet Bakırcıoğlu; Jennifer Moliterno Günel; M Necmettin Pamir; Ketu Mishra-Gorur; Kaya Bilguvar; Katsuhito Yasuno; Alexander Vortmeyer; Anita J Huttner; Chris Sander; Murat Günel
Journal:  Neuro Oncol       Date:  2015-03-03       Impact factor: 12.300

3.  Epidemiology of glial and non-glial brain tumours in Europe.

Authors:  Emanuele Crocetti; Annalisa Trama; Charles Stiller; Adele Caldarella; Riccardo Soffietti; Jana Jaal; Damien C Weber; Umberto Ricardi; Jerzy Slowinski; Alba Brandes
Journal:  Eur J Cancer       Date:  2012-01-07       Impact factor: 9.162

4.  Simplified identification of Lynch syndrome: a prospective, multicenter study.

Authors:  Delphine Bonnet; Janick Selves; Christine Toulas; Marie Danjoux; Jean Pierre Duffas; Guillaume Portier; Sylvain Kirzin; Laurent Ghouti; Nicolas Carrère; Bertrand Suc; Laurent Alric; Karl Barange; Louis Buscail; Thierry Chaubard; Kamran Imani; Rosine Guimbaud
Journal:  Dig Liver Dis       Date:  2012-04-03       Impact factor: 4.088

Review 5.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

6.  Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.

Authors:  Tanner M Johanns; Christopher A Miller; Ian G Dorward; Christina Tsien; Edward Chang; Arie Perry; Ravindra Uppaluri; Cole Ferguson; Robert E Schmidt; Sonika Dahiya; George Ansstas; Elaine R Mardis; Gavin P Dunn
Journal:  Cancer Discov       Date:  2016-09-28       Impact factor: 39.397

Review 7.  A panoply of errors: polymerase proofreading domain mutations in cancer.

Authors:  Emily Rayner; Inge C van Gool; Claire Palles; Stephen E Kearsey; Tjalling Bosse; Ian Tomlinson; David N Church
Journal:  Nat Rev Cancer       Date:  2016-02       Impact factor: 60.716

8.  A mutation in POLE predisposing to a multi-tumour phenotype.

Authors:  Anna Rohlin; Theofanis Zagoras; Staffan Nilsson; Ulf Lundstam; Jan Wahlström; Leif Hultén; Tommy Martinsson; Göran B Karlsson; Margareta Nordling
Journal:  Int J Oncol       Date:  2014-04-29       Impact factor: 5.650

Review 9.  POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.

Authors:  Fernando Bellido; Marta Pineda; Gemma Aiza; Rafael Valdés-Mas; Matilde Navarro; Diana A Puente; Tirso Pons; Sara González; Silvia Iglesias; Esther Darder; Virginia Piñol; José Luís Soto; Alfonso Valencia; Ignacio Blanco; Miguel Urioste; Joan Brunet; Conxi Lázaro; Gabriel Capellá; Xose S Puente; Laura Valle
Journal:  Genet Med       Date:  2015-07-02       Impact factor: 8.822

Review 10.  Replicative DNA polymerase mutations in cancer.

Authors:  Ellen Heitzer; Ian Tomlinson
Journal:  Curr Opin Genet Dev       Date:  2014-02-26       Impact factor: 5.578

View more
  10 in total

1.  Probing the mechanisms of two exonuclease domain mutators of DNA polymerase ϵ.

Authors:  Joseph M Dahl; Natalie Thomas; Maxwell A Tracy; Brady L Hearn; Lalith Perera; Scott R Kennedy; Alan J Herr; Thomas A Kunkel
Journal:  Nucleic Acids Res       Date:  2022-01-25       Impact factor: 16.971

Review 2.  Opportunities for new studies of nuclear DNA replication enzymology in budding yeast.

Authors:  Marta A Garbacz; Scott A Lujan; Thomas A Kunkel
Journal:  Curr Genet       Date:  2019-09-06       Impact factor: 3.886

3.  Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment.

Authors:  Valeria Barresi; Michele Simbolo; Andrea Mafficini; Maria Liliana Piredda; Maria Caffo; Salvatore Massimiliano Cardali; Antonino Germanò; Sara Cingarlini; Claudio Ghimenton; Aldo Scarpa
Journal:  Cancers (Basel)       Date:  2019-08-30       Impact factor: 6.639

4.  Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma.

Authors:  Tiffany G Baker; Jay Alden; Adrian M Dubuc; Cynthia T Welsh; Iya Znoyko; Linda D Cooley; Midhat S Farooqi; Stuart Schwartz; Yvonne Y Li; Andrew D Cherniack; Scott M Lindhorst; Melissa Gener; Daynna J Wolff; David M Meredith
Journal:  Neurooncol Adv       Date:  2020-11-12

Review 5.  Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.

Authors:  Jernej Gašperšič; Alja Videtič Paska
Journal:  Biochem Med (Zagreb)       Date:  2020-08-05       Impact factor: 2.313

6.  POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.

Authors:  Yiran Li; Yiding Bian; Kai Wang; Xiao-Ping Wan
Journal:  BMC Med Genet       Date:  2019-12-21       Impact factor: 2.103

7.  New Pathogenic Germline Variants in Very Early Onset and Familial Colorectal Cancer Patients.

Authors:  Malene Djursby; Majbritt B Madsen; Jane H Frederiksen; Lukas A Berchtold; Christina Therkildsen; Gro L Willemoe; Jane P Hasselby; Friedrik Wikman; Henrik Okkels; Anne-Bine Skytte; Mef Nilbert; Karin Wadt; Anne-Marie Gerdes; Thomas van Overeem Hansen
Journal:  Front Genet       Date:  2020-09-24       Impact factor: 4.599

8.  IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.

Authors:  Valeria Barresi; Michele Simbolo; Andrea Mafficini; Maurizio Martini; Martina Calicchia; Maria Liliana Piredda; Chiara Ciaparrone; Giada Bonizzato; Serena Ammendola; Maria Caffo; Giampietro Pinna; Francesco Sala; Rita Teresa Lawlor; Claudio Ghimenton; Aldo Scarpa
Journal:  Acta Neuropathol Commun       Date:  2021-12-24       Impact factor: 7.801

9.  Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.

Authors:  Jieer Ying; Lin Yang; Jiani C Yin; Guojie Xia; Minyan Xing; Xiaoxi Chen; Jiaohui Pang; Yong Wu; Hua Bao; Xue Wu; Yang Shao; Lingjun Zhu; Xiangdong Cheng
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

10.  The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management.

Authors:  Claire Palles; Lynn Martin; Enric Domingo; Laura Chegwidden; Josh McGuire; Vicky Cuthill; Ellen Heitzer; Rachel Kerr; David Kerr; Stephen Kearsey; Susan K Clark; Ian Tomlinson; Andrew Latchford
Journal:  Fam Cancer       Date:  2021-05-05       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.